JP2020537501A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537501A5
JP2020537501A5 JP2020515158A JP2020515158A JP2020537501A5 JP 2020537501 A5 JP2020537501 A5 JP 2020537501A5 JP 2020515158 A JP2020515158 A JP 2020515158A JP 2020515158 A JP2020515158 A JP 2020515158A JP 2020537501 A5 JP2020537501 A5 JP 2020537501A5
Authority
JP
Japan
Prior art keywords
composition
antisense oligomer
administered
exon
oligomer conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537501A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/066509 external-priority patent/WO2018118662A1/en
Application filed filed Critical
Priority claimed from PCT/US2018/035660 external-priority patent/WO2019059973A1/en
Publication of JP2020537501A publication Critical patent/JP2020537501A/ja
Publication of JP2020537501A5 publication Critical patent/JP2020537501A5/ja
Pending legal-status Critical Current

Links

JP2020515158A 2017-09-22 2018-06-01 筋ジストロフィーのためのエクソンスキッピングオリゴマーコンジュゲート Pending JP2020537501A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762562146P 2017-09-22 2017-09-22
US62/562,146 2017-09-22
PCT/US2017/066509 WO2018118662A1 (en) 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy
USPCT/US2017/066509 2017-12-14
PCT/US2018/035660 WO2019059973A1 (en) 2017-09-22 2018-06-01 OLIGOMERIC CONJUGATES FOR THE EXON JUMP FOR MUSCLE DYSTROPHY

Publications (2)

Publication Number Publication Date
JP2020537501A JP2020537501A (ja) 2020-12-24
JP2020537501A5 true JP2020537501A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=65810491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515158A Pending JP2020537501A (ja) 2017-09-22 2018-06-01 筋ジストロフィーのためのエクソンスキッピングオリゴマーコンジュゲート

Country Status (9)

Country Link
US (1) US20200377886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020537501A (cg-RX-API-DMAC7.html)
KR (1) KR20200057029A (cg-RX-API-DMAC7.html)
AU (1) AU2018336569A1 (cg-RX-API-DMAC7.html)
CA (1) CA3075964A1 (cg-RX-API-DMAC7.html)
EA (2) EA201991450A1 (cg-RX-API-DMAC7.html)
IL (1) IL273289A (cg-RX-API-DMAC7.html)
MX (1) MX2020003227A (cg-RX-API-DMAC7.html)
WO (1) WO2019059973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3464305T3 (da) 2016-05-24 2024-10-28 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af oligomerer
PL3554552T3 (pl) * 2016-12-19 2022-11-21 Sarepta Therapeutics, Inc. Koniugaty oligomerów do pomijania egzonów dla dystrofii mięśniowej
MY205600A (en) 2016-12-19 2024-10-29 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2020209285A1 (ja) * 2019-04-08 2020-10-15 国立大学法人東京医科歯科大学 筋疾患治療用医薬組成物
EP3955966A1 (en) * 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
WO2020257489A1 (en) * 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
WO2021077000A1 (en) 2019-10-16 2021-04-22 The Broad Institute, Inc. Engineered muscle targeting compositions
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20240168981A (ko) * 2022-03-02 2024-12-02 웨이브 라이프 사이언시스 리미티드 엑손 스키핑을 위한 올리고뉴클레오티드 조성물 및 이의 방법
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
AU5698186A (en) 1985-03-15 1986-10-13 Summerton, J. Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
EP0698092B1 (en) 1993-05-11 2007-07-25 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6683173B2 (en) 1998-04-03 2004-01-27 Epoch Biosciences, Inc. Tm leveling methods
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
JP2000125448A (ja) 1998-10-14 2000-04-28 Yazaki Corp 電気接続箱
JP2000256547A (ja) 1999-03-10 2000-09-19 Sumitomo Dow Ltd 耐熱性プラスチックカード用樹脂組成物
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
AU2281201A (en) 1999-12-29 2001-07-09 A. James Mixson Histidine copolymer and methods for using same
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003295388A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-substituted oligomeric compounds and compositions for use in gene modulations
EP2386636B1 (en) 2002-11-25 2016-01-27 Masafumi Matsuo Ena nucleic acid drugs modifying splicing in mrna precursor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
NZ563206A (en) 2005-04-22 2009-09-25 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007058894A2 (en) 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
JP3151554U (ja) 2006-05-17 2009-07-02 スヴェトラナ アナトレフナ ソコロヴァ 輸送手段
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
EP2207779B1 (en) 2007-11-15 2014-04-09 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) * 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
PT2344637E (pt) 2008-10-27 2015-03-23 Academisch Ziekenhuis Leiden Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2758189C (en) 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2010123369A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
PL2499249T3 (pl) 2009-11-12 2019-03-29 Univ Western Australia Cząsteczki antysensowne i sposoby leczenia patologii
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
KR20140052963A (ko) 2011-02-08 2014-05-07 더 샬롯테-맥클렌버그 하스피털 오쏘러티 디/비/에이 카롤리나스 헬스케어 시스템 안티센스 올리고뉴클레오티드
CN103619356B (zh) * 2011-05-05 2017-09-12 萨勒普塔医疗公司 肽寡核苷酸缀合物
ES2535654T3 (es) 2011-10-13 2015-05-13 Association Institut De Myologie ADN triciclo-fosforotioato
US9512424B2 (en) 2011-12-28 2016-12-06 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
DE102012101676A1 (de) 2012-02-29 2013-08-29 Klaus-Dieter Rösler Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage
CA2877644A1 (en) 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
WO2014100714A1 (en) * 2012-12-20 2014-06-26 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
BR122020016865B1 (pt) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
NZ631132A (en) * 2013-03-14 2017-06-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
RS58573B1 (sr) 2014-03-12 2019-05-31 Nippon Shinyaku Co Ltd Antisensna nukleinska kiselina
TWI666317B (zh) 2014-06-17 2019-07-21 Nippon Shinyaku Co., Ltd. 反義核酸
CA2966527C (en) 2014-11-02 2024-02-06 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
BR112018007066A2 (pt) * 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
CN114533900A (zh) 2015-10-09 2022-05-27 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA45290A (fr) 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
PL3554552T3 (pl) * 2016-12-19 2022-11-21 Sarepta Therapeutics, Inc. Koniugaty oligomerów do pomijania egzonów dla dystrofii mięśniowej
EP3955966A1 (en) * 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Similar Documents

Publication Publication Date Title
JP2020537501A5 (cg-RX-API-DMAC7.html)
JP2020503010A5 (cg-RX-API-DMAC7.html)
JP2020503009A5 (cg-RX-API-DMAC7.html)
JP2020511943A5 (cg-RX-API-DMAC7.html)
JP2015504650A5 (cg-RX-API-DMAC7.html)
JP2018530560A5 (cg-RX-API-DMAC7.html)
JP2010531879A5 (cg-RX-API-DMAC7.html)
JP2019518741A5 (cg-RX-API-DMAC7.html)
JP2012506703A5 (cg-RX-API-DMAC7.html)
JP2010513285A5 (cg-RX-API-DMAC7.html)
JP2011509258A5 (cg-RX-API-DMAC7.html)
JP2012505250A5 (cg-RX-API-DMAC7.html)
JP2019501133A5 (cg-RX-API-DMAC7.html)
JP2008531537A5 (cg-RX-API-DMAC7.html)
JP2016533761A5 (cg-RX-API-DMAC7.html)
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2020519676A5 (cg-RX-API-DMAC7.html)
US8722640B2 (en) Stabilized STAT3 decoy oligonucleotides and uses therefor
JP2011506274A5 (cg-RX-API-DMAC7.html)
TW201010698A (en) Treatment or prevention of hepatitis C with immunomodulator compounds
JP2017214420A (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
JP2004502755A5 (cg-RX-API-DMAC7.html)
JP2018506272A5 (cg-RX-API-DMAC7.html)
JP2019527549A5 (cg-RX-API-DMAC7.html)
JPWO2019231824A5 (cg-RX-API-DMAC7.html)